Today: 10 June 2026
Browse Category

NASDAQ:GH 30 October 2025 - 5 May 2026

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx shares dropped 51% to $33.12 after the company cut its 2026 revenue forecast and lowered full-year guidance to $475–$490 million. First-quarter revenue rose 17% to $102.3 million, but missed expectations as reimbursement rates and product mix hurt sales. The company posted an adjusted net loss of $8.2 million. Management maintained its target for positive adjusted net income this year.
5 May 2026
····
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health shares jumped 7.2% to $109.24 Tuesday, nearing their 52-week high, despite Evercore ISI downgrading the stock while raising its price target to $105. A Form 4 filing showed Chief People Officer Terilyn J. Monroe received 17,555 shares through vested stock units. Shares have climbed about 200% in the past year. Investors are watching Medicare reimbursement rates for Guardant’s Shield blood test.
6 January 2026
·
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··

Stock Market Today

  • Payoneer Global (PAYO) Valuation Outlook Amid Recent Share Price Surge
    June 10, 2026, 12:09 PM EDT. Payoneer Global (PAYO) shares rose 38% over 90 days to US$6.39, yet the 1-year return lags at -6.85%. Analysts project annual revenue growth of 9.7% and expanding profit margins from 7% to 11.5% in three years, supporting a 15% undervaluation with a fair value estimate of US$7.50. However, PAYO trades at a high price-to-earnings (P/E) ratio of 29.6x, well above the Diversified Financial sector average of 16.5x and peers at 19.5x, signaling valuation risk if growth falters. Investors should weigh growth potential against competition, regulatory costs, and a premium multiple that could compress quickly. The key question remains whether earnings quality and future growth justify this premium valuation.

Latest articles

Euro Tech Holdings Shares Slip on High-Volume CLWT Ballast-Water Launch

Euro Tech Holdings Shares Slip on High-Volume CLWT Ballast-Water Launch

10 June 2026
Euro Tech Holdings’ CLWT shares plunged 11.7% to $1.13 on heavy volume after launching a mobile hybrid ballast-water treatment facility, but the company’s announcement lacked customer names, order values, pricing, or a European sales partner, leaving investors with more questions than answers as the stock’s move outpaced any disclosed commercial progress.
Ming Shing Group Holdings shares surge, then fall back after $110M graphene move raises dilution questions

Ming Shing Group Holdings shares surge, then fall back after $110M graphene move raises dilution questions

10 June 2026
Ming Shing Group Holdings shares soared to $5.54 before plunging to $1.74 after closing a $110 million acquisition of PMA Nano Carbon Tech, paid with convertible notes that could create over 111 million new shares at $0.99 each, raising dilution concerns as investors weigh the company’s pivot from construction to graphene technology amid management turnover and a June 16 vote on massively increasing authorized shares.
Go toTop